In clinical trials

Immune & defense

LL-37

Evidence

Early clinical trials

Class

Human cathelicidin antimicrobial peptide

KEY TAKEAWAY

LL-37 is the only cathelicidin antimicrobial peptide made by human cells. It kills microbes and shapes immune responses. A small phase 2 trial tested it on hard-to-heal leg ulcers.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

The body's own antimicrobial defense peptide

Studied for

Chronic wound healing and infection

Key fact

A small randomized trial in venous leg ulcers reported improved healing

Route

Topical (investigational)

Evidence strength

Early clinical trials

What it is

What it is

LL-37 is a 37-amino-acid peptide released from a larger protein when immune cells and skin cells detect infection.

How it works

How it works

It disrupts microbial membranes and signals immune cells. It also influences cell migration and blood vessel growth during wound repair.

Regulatory status

Regulatory status

LL-37 is not approved by the FDA. It remains investigational.

What it is used for

What it is used for

Studied for wounds, skin infections and as a model for new antimicrobial drugs.

Side effects and risks

Side effects and risks

Topical use was well tolerated in a small trial. High levels have been linked to inflammation in some skin conditions, so more safety work is needed.

Citations

Citations

Grönberg A et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers. Wound Repair Regen. 2014;22:613-621.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo